Sun Pharma forays into Japan with $293 million product buy from Novartis
pharmafile | March 30, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Japan, M&A, MA, Novartis, Sun Pharma, generics
Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the acquisition of 14 brands in Japan from Swiss pharma major Novartis (VTX: NOVN) for $293 million.
Under the terms of the deal, Novartis will continue to distribute these brands, for a certain period, pending transfer of all marketing authorizations to Sun Pharma.
Novartis brands had combined annualized revenues of about $160 million and address medical conditions across several therapeutic areas, the company said in a statement.
Sun Pharma’s managing director, Dilip Shanghvi, says: “Japan is a market of strategic interest for us. This acquisition marks Sun Pharma’s foray into the Japanese prescription market and provides us an opportunity to build a larger product portfolio in the future.”
The Japanese pharmaceutical market is estimated to be worth $73 billion, accounting for over 7% of the $1 trillion global pharmaceutical market.
Shares in the company were trading up over 2% at 810.50 rupees on the Bombay Stock Exchange Wednesday.
Anjali Shukla
Related Content
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
Novartis shares new data for Zolgensma in children with SMA
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …
Novartis to acquire MorphoSys AG for €2.7bn
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …